Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCB-2019 COVID-19 Vaccine in Patients with Immune-Mediated Inflammatory Diseases
NCT05012787Phase 3Terminated
- Sponsor
- Clover Biopharmaceuticals
- Start
- Nov 2021
- Primary completion
- Mar 2022
- Countries
- 1
01
Overview
A Phase 3 trial of SCB-2019 in coronavirus disease 2019 (COVID-19), sponsored by Clover Biopharmaceuticals. Started Nov 2021; status: terminated.
02
Drugs
SCB-2019
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05012787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05012787.